KEGG   DRUG: Teneligliptin and canagliflozin
Entry
D10897            Mixture   Drug                                   

Name
Teneligliptin and canagliflozin;
Teneligliptin and canagliflozin;
Canalia (TN)
Component
(Teneligliptin hydrobromide hydrate [DR:D09756] | Teneligliptin [DR:D08616]), Canagliflozin [DR:D09592]
Remark
Therapeutic category: 3969
Product: D10897<JP>
Efficacy
Antidiabetic
Comment
Teneligliptin is a substrate of CYP3A4, FMO1 and FMO3.
Canagliflozin is a substrate of UGT1A9 and UGT2B4.
Teneligliptin and Canagliflozin are inhibitor and substrate of P-gp.
Metabolism
Enzyme: CYP3A4 [HSA:1576], FMO1 [HSA:2326], FMO3 [HSA:2328], UGT1A9 [HSA:54600], UGT2B4 [HSA:7363]
Transporter: ABCB1 [HSA:5243]
Interaction
Transporter inhibition: ABCB1 [HSA:5243]
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   396  Antidiabetic agents
    3969  Others
     D10897  Teneligliptin and canagliflozin
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10897
 Drug transporters
  D10897
Other DBs
PubChem: 340650301
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system